CCI nod for addl stake of Valuedrive Technologies by Setu AIF Trust, Konark Trust, and MMPL Trust (See 'Corp Brief') CCI approves stake of Groww Asset Management by State Street Global Advisors (See 'Corp Brief') CCI approves acquisition of equity in Shriram Finance by MUFG Bank (See 'Corp Brief') CCI approves merger of Chess Merger Sub with and into Udemy Inc. (See 'Corp Brief') IBC - Non-inclusion of claim in resolution plan results in its extinguishment, and any claim which is not expressly included in resolution plan, and which is not expressly barred as per such plan, cannot be inferred: SC (See 'Legal Desk') CCI okays subscription of equity of Aditya Birla Renewables by GIP EM Star (See 'Corp Brief') Reddy calls for Accelerated Exploration of Critical Minerals at NMEDT Governing Body Meeting (See 'Corp Brief') National Centre to promote organic and natural farming (See 'Corp Brief') PMLA - Recourse to LOC can be taken by investigating agency in cognizable offences if accused is deliberately evading arrest or not appearing in trial court despite Non-Bailable Warrants: HC (See 'Legal Desk') Bharat 6G Alliance expands six-fold, emerging as key driver of 6G ambitions (See 'Corp Brief') Semicon India Programme boosts domestic Chip Manufacturing and Design Ecosystem (See 'Corp Brief') TRAI undertakes assessment of quality of service by conducting drive test (See 'Corp Brief') A&C - Once strong prima facie case of copyright infringement is established, interim injunction to protect copyright must typically follow: HC (See 'Legal Desk') CSR Conclave: 'Empowering Tribals through CSR' (See 'Corp Brief') CSIR & MEA jointly host Ambassadors from Global South (See 'Corp Brief') Nadda reaffirms India's Commitment to Eliminate TB Ahead of Global Targets (See 'Corp Brief') Ministry of Ayush and DBT announce collaborative Clinical Study on Ayurveda (See 'Corp Brief') IBC - Issues of fraud or existence of debt must be decided by insolvency tribunal, not civil court: HC (See 'Legal Desk') RBI strengthens Framework on Unauthorised Electronic Banking Transactions (See 'Corp Brief') Govt expands DEH Initiative to Boost District-Level Export Competitiveness (See 'Corp Brief') DPIIT signs MoU with leading AC company to strengthen manufacturing ecosystem (See 'Corp Brief') Two-Day Eastern Region Review Meeting of CGCA concludes (See 'Corp Brief') IPR - Minor variations in product that do not alter essential mode of operation of patented invention are considered mere engineering variations: HC (See 'Legal Desk') Paatil calls for 'Jan Bhagidari' to strengthen Water Conservation Efforts (See 'Corp Brief') IICA successfully concludes 4th Batch of Directors' Certification in Corporate Governance (See 'Corp Brief') Ministry of MSME assisting entrepreneurs in setting up of new micro enterprises (See 'Corp Brief') COFEPOSA - Dispute over rent or mesne profits for immovable property leased for commercial purposes is 'commercial dispute': HC (See 'Legal Desk') Amendments to Banking Regulation Act and MSCS Act, 2002 enhance oversight & accountability (See 'Corp Brief') MY Bharat mobilises Youth across 763 Districts for Shaheed Diwas Padyatra (See 'Corp Brief') PMLA - Even property acquired prior to commission of crime can be provisionally attached finding it falling in definition of 'proceeds of crime': SAFEMA (See 'Legal Desk') Ministry of Mines to launch 7th Tranche of Auction of Critical and Strategic Minerals (See 'Corp Brief') Jal Mahotsav 2026 gives momentum to 'Jal Sanchay se Jan Bhagidari' (See 'Corp Brief') Ministry of Mines to organise National DMF Summit 2026 (See 'Corp Brief') PMLA - High Court of Delhi lacked territorial jurisdiction to hear appeal filed against Appellant based in Kolkata; GST registration at Delhi, occasional hearings before Delhi Bench of NCLT do not establish that appellant ordinarily operates in Delhi: HC (See 'Legal Desk') Union Minister chairs 90th Meeting of Standing Committee of National Board for Wildlife (See 'Corp Brief') India achieves 1 billion Tonne Coal Production Milestone Again (See 'Corp Brief') Capital Market - SEBI's regulations are framed to protect rights of stakeholders in securities market, and violation of its regulations being matter of public law, can't be condoned by private resolution of shareholders: SC (See 'Legal Desk') PDUNASS conducts DoPT-Sponsored Training Programme (See 'Corp Brief') Govt introduces Credit Guarantee Scheme for Microfinance Institutions-2.0 (See 'Corp Brief') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

Govt hosts workshop on increasing R&D in pharma-medical tech sector

Published: Mar 13, 2025

By TIOLCorplaws News Service

NEW DELHI, MAR 13, 2025: THE Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, organised a workshop on the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) Scheme today. The workshop was inaugurated in the presence of the Secretaries of five stakeholder Ministries and Departments of the Government of India, namely, Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General (DG), Council of Scientific and Industrial Research (CSIR); and Dr Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, Indian Council for Medical Research (ICMR). The workshop served as a platform for identifying key action points and approaches to further the shared commitment to promote research and development in the pharmaceuticals and medical technologies sector.

Amit Agrawal, Secretary, Department of Pharmaceuticals highlighted the rapid expansion in the sector, underscoring the importance of research and innovation in driving making and innovating in India for India and the world. In this regard, he highlighted that the global share of personalised and precision technology platforms (such as antibody-drug conjugates, bi-specific antibodies, and cell and gene therapy) among the top-100 drugs by value is growing rapidly, from 5% in 2020 to 9% in 2025 and projected to grow to 20% by 2030. He also highlighted the 10 times increase in the number of Indian healthcare and life sciences startups over the last four years, from over 900 in 2020 to more than 10,000 in 2024, as well as the growing pipeline of innovative products of Indian firms.

Amit Agrawal said that the groundwork and the pipeline for projects for the PRIP scheme has been laid through this growing innovation ecosystem of Indian startups and industry, supported by a wide array of initiatives of the scientific Ministries/ Departments. The latter include the clinical trial network created by CSIR under its INTENT initiative; the patenting support available through DST's TIFAC and ICMR's Patent Mitra initiative; the handholding support available to both medical technology and drug innovations through ICMR's MedTech Mitra initiative; the funding support available to startups through Department of Biotechnology's BIRAC, MeitY's TIDE 2.0 and SAMRIDH schemes and DST's Quantum Computing Mission, etc.

Reiterating the Government's commitment to a robust research ecosystem, Amit said that PRIP is a transformative initiative aimed at catalysing innovation, strengthening industry-academia linkages, and positioning India as a global leader in pharmaceutical and MedTech research.

Prof. Abhay Karandikar, Secretary, DST underscored the importance of cutting-edge scientific research in driving advancements in pharmaceuticals and MedTech, reinforcing India's healthcare ecosystem and highlighted the supports available through the extensive incubator and accelerator network of DST.

S. Krishnan, Secretary, MeitY emphasised the transformative potential of digital health, artificial intelligence (AI) and data-driven technologies in drug discovery and medical device development. He highlighted the research strengths of MeitY's organisations, such as Society for Applied Microwave Electronics Engineering and Research (SAMEER), C-DAC and Centre for Materials for Electronics Technology (C-MET).

Dr Rajiv Bahl, Secretary, DHR and DG, ICMR highlighted the critical role of clinical research, indigenous drug development and regulatory advancements in accelerating pharmaceutical innovation. He offered the full support of the ICMR INTENT, MedTech Mitra and Patent Mitra initiatives in taking forward the shared goals of PRIP scheme. He also said that the industry-academia collaborative research window under the scheme could be of considerable help in taking forward the large volume of intramural and extramural research being funded by ICMR to the market with funding from PRIP and industry involvement.

Dr N. Kalaiselvi, Secretary, DSIR and DG, CSIR underscored the need to foster a culture of scientific collaboration between research institutions and industry to ensure the seamless translation of research into commercially viable applications. She highlighted that considerable research done in CSIR labs could be taken to the market through collaboration with industry and funding from PRIP.

The discussions reaffirmed the Government's vision of transforming India into a global hub for research and innovation in pharmaceuticals and medical technology. The workshop featured four dedicated breakout sessions, bringing together over 100 participants from leading scientific departments and premier institutions, including the National Institutes of Pharmaceutical Education and Research, IITs, CSIR labs and organisations of ICMR, MeitY, DST and Department of Bio technology, along with key government enablers for the ecosystem. Key deliberations covered the emerging trends in pharmaceutical and MedTech research, strategies for translating research into commercially viable products, government support mechanisms to accelerate sectoral growth and flexibilities sought to maximise the impact from the PRIP scheme.

All participants were requested to share their suggestions in the Expression of Interest (EoI) form for the PRIP scheme hosted on the website of the Department of Pharmaceuticals, so that these may be taken into account while taking forward the scheme and enabling participants. The EoI would be open till April 7, 2025.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.